Step 1: Intake form.
Before a clinician sees you, they need context — the same context any good primary-care physician would gather at a first appointment. A well-built telehealth platform starts with a structured medical-history questionnaire: current medications and doses, active conditions, known allergies (drug and environmental), relevant family history, and a clear statement of what the patient is trying to accomplish. On a good platform, this is the same intake instrument a clinic would use — just asynchronous, completed at the patient’s pace, and stored in a format the clinician can review before the visit begins rather than in a stack of photocopied paper forms.
Quality varies significantly here. Some platforms ask five questions and call it intake. Others walk through detailed medication histories, prior workups, imaging results, and social history. The depth of the intake form is a reliable proxy for how seriously a platform takes clinical thoroughness. A questionnaire that takes eight minutes to complete is not inconvenient — it is doing its job.
Step 2: Lab work.
Most telehealth conditions worth managing — hormonal imbalances, metabolic dysfunction, thyroid disorders, cardiovascular risk factors — are not diagnosable from a conversation alone. Lab work is required, and a serious platform has a clear path to getting it done. Two common routes exist. The first is a mail-in finger-prick kit: a small collection device arrives by mail, the patient performs a simple capillary blood draw at home, and the dried blood card ships back to the laboratory. These kits work well for basic panels — lipids, glucose, HbA1c, thyroid function — and remove the friction of a physical lab visit entirely.
The second route is a lab requisition for a phlebotomy draw at a local Quest Diagnostics or LabCorp patient service center — the appropriate approach for full comprehensive metabolic panels, hormone panels requiring serum samples, kidney and liver function panels, and any test requiring a larger or more carefully handled specimen. Results flow back into the platform portal within one to three business days, at which point the clinician can review them in context of the patient’s intake before the video visit. The best platforms display your results with reference ranges and a clinician annotation rather than raw numbers with no explanation.
Step 3: Clinician video consult.
The video visit is the clinical core of the encounter — not a formality. A standard telehealth consultation runs 20 to 30 minutes with a board-certified clinician who holds an active license in the patient’s state. By the time this call begins, the clinician has reviewed the intake form, has the lab results in front of them, and has a working clinical picture. That preparation changes the quality of the conversation: rather than spending the first ten minutes establishing baseline history, the clinician can spend those minutes on the clinical reasoning that matters — reviewing what the numbers mean for this specific patient, asking follow-up questions about timeline, symptom burden, and prior treatment responses, and discussing the patient’s actual goals.
This is the same clinical reasoning conversation that happens in a primary-care office. The modality is different — video rather than in-person — but the cognitive work is identical. A clinician who is reviewing your TSH trend over two years and discussing whether your current dose is optimized is practicing the same medicine they would practice in an exam room. The visit should feel like a real clinical conversation, not a checkbox exercise designed to generate a prescription.
Step 4: Treatment plan and (if appropriate) prescription.
After the visit, the clinician documents a formal assessment and plan — the same structured note a physician would write in an EMR after an in-person visit. The patient receives a written copy of this plan in their secure portal: what was assessed, what was recommended, what was prescribed, and what the follow-up plan looks like. If a prescription is clinically appropriate, it routes electronically. Standard medications go to the patient’s preferred retail or mail-order pharmacy via e-prescribe, typically the same day as the visit.
Medications that are not commercially available as FDA-approved products — or that need to be formulated in a non-standard dose, route, or combination — route instead to a compounding pharmacy. In the United States, these pharmacies operate under either 503A (patient-specific, prescription-required) or 503B (outsourcing facility, sterile, larger-batch) frameworks regulated by the FDA and state boards of pharmacy. The prescribing clinician determines which route is clinically appropriate; the platform facilitates the routing. The patient ends up with a written plan, a prescription if warranted, and a clear record of what was decided and why.
Step 5: Ongoing follow-up and dose adjustment.
A single consult is not a care relationship. The ongoing layer of a telehealth platform is what separates platforms built around clinical continuity from those built around transaction volume. Between formal visits, asynchronous secure messaging allows patients to report how they are tolerating a protocol, flag a side effect, or ask a clarifying question — and receive a response from their clinical team without booking another full video appointment.
Periodic video re-visits — typically on a four-to-twelve week cadence depending on the condition, protocol, and patient response — allow the clinician to formally assess progress, review updated labs, and adjust the treatment plan as warranted. Lab repeats are scheduled as clinically appropriate: some patients need a repeat panel at six weeks, others at six months. A well-run platform tracks this and prompts both clinician and patient when a follow-up or repeat lab is due. The goal is a care relationship that evolves with the patient, not a one-and-done consult with no mechanism for adjustment.
What this looks like for peptide-focused care specifically.
The five steps above apply to peptide-related telehealth in the same way they apply to any other condition managed remotely — with a few important particulars worth naming. During the intake and video consult, the clinician evaluates whether a peptide protocol is clinically appropriate given the patient’s goals, current health status, comorbidities, and risk profile. This evaluation is substantive, not cursory: a patient’s candidacy depends on their medical history, any contraindications, and whether the intended clinical objective is one the available evidence supports.
If the clinician determines that a protocol is appropriate and the medication is legally available in the patient’s jurisdiction, the prescription routes to a 503A compounding pharmacy — a patient-specific compound prepared by a licensed pharmacist under a valid prescription, subject to state board of pharmacy oversight. Ongoing labs play a central role in this type of care: periodic panels assess response, track relevant safety markers, and give the clinician the data needed to make informed adjustments at each follow-up visit.
What distinguishes a well-run platform in this space is continuity. A patient pursuing a peptide protocol is not dropped after the initial consult and left to manage their own follow-up. The platform maintains the care relationship — scheduling re-visits, flagging when labs are due, facilitating asynchronous check-ins between visits — so that adjustments are made by a clinician who knows the patient’s full picture, not by a patient making decisions in the absence of clinical oversight.
Stay informed.
Infrequent research briefs — regulatory updates, clinical evidence, platform reviews. No filler.